|
Medical News Cost-Benefit Analysis of Treatment as Prevention Compared With Circumcision, Antiretroviral TherapyDecember 7, 2012 In a study published online in the Proceedings of the National Academy of Sciences, Till Barnighausen, David Bloom, and Salal Humair of the Harvard School of Public Health examine "whether [HIV treatment as prevention (TasP)] is indeed a game changer or if comparable benefits are obtainable at similar or lower cost by increasing coverage of medical male circumcision (MMC) and antiretroviral treatment (ART)." They write, "The most cost-effective HIV prevention strategy is to expand MMC coverage and then scale up ART, but the most cost-effective HIV-mortality reduction strategy is to scale up MMC and ART jointly. TasP is cost effective by commonly used absolute benchmarks but it is far less cost effective than MMC and ART" (12/6). Back to other news for December 2012
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|